XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 31.16

-3.2%

Dec 1 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: LarryS who wrote (16455)	11/20/2003 1:15:17 AM
From: Bluegreen	of 17367

Larry, you might want to post this over and over again at the swamp......it is from the link I just provided. Slogan from DNA and Xoma should be.....You think you like the results now........You ain't seen NOTHING yet!!!!!!>>>>>>>Additionally, 21 months (84 weeks) of data from an open-label study evaluating the long-term safety and tolerability of continuous Raptiva will be presented. The 21-month data analysis results showed that 67 percent (130/194) of patients achieved a PASI 75 response with weekly Raptiva therapy. "These data further support the sustained and potentially increased clinical benefit of Raptiva when administered continuously for the treatment of moderate-to-severe plaque psoriasis," said Hal Barron M.D., F.A.C.C., Genentech's vice president, Medical Affairs.<<<<<<<<<<

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next